Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

Shirato K, Kawase M, Matsuyama S.

J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13.

2.

Protease inhibitors targeting coronavirus and filovirus entry.

Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G.

Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011.

3.

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.

Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S.

J Virol. 2012 Jun;86(12):6537-45. doi: 10.1128/JVI.00094-12.

4.

Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation.

Qian Z, Dominguez SR, Holmes KV.

PLoS One. 2013 Oct 3;8(10):e76469. doi: 10.1371/journal.pone.0076469.

5.

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.

Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F.

J Virol. 2010 Dec;84(24):12658-64. doi: 10.1128/JVI.01542-10.

6.

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium.

Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, Glowacka I, Welsch K, Winkler M, Schneider H, Hofmann-Winkler H, Thiel V, Pöhlmann S.

J Virol. 2013 Jun;87(11):6150-60. doi: 10.1128/JVI.03372-12.

7.

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein.

Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S.

Virus Res. 2014 Dec 19;194:200-10. doi: 10.1016/j.virusres.2014.10.007. Review.

PMID:
25451066
8.

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.

Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pöhlmann S.

J Virol. 2011 May;85(9):4122-34. doi: 10.1128/JVI.02232-10.

9.

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.

de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Bárcena M, Haagmans BL, Snijder EJ, van den Hoogen BG.

J Gen Virol. 2013 Aug;94(Pt 8):1749-60. doi: 10.1099/vir.0.052910-0.

10.

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection.

Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, Jiang S.

J Infect Dis. 2015 Dec 15;212(12):1894-903. doi: 10.1093/infdis/jiv325.

11.

Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry.

Shirato K, Kanou K, Kawase M, Matsuyama S.

J Virol. 2016 Dec 16;91(1). pii: e01387-16.

PMID:
27733646
12.

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.

Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS, Harrison SC, Dormitzer PR, Farzan M, Rottier PJ, Choe H.

J Biol Chem. 2006 Feb 10;281(6):3198-203.

13.

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.

Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y.

Virol J. 2013 Aug 26;10:266. doi: 10.1186/1743-422X-10-266.

14.

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis.

Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, Sun T, Lau CC, Wong KK, Chan JY, Chan JF, To KK, Chan KH, Zheng BJ, Yuen KY.

J Infect Dis. 2014 May 1;209(9):1331-42. doi: 10.1093/infdis/jit504.

15.

Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus.

Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21. doi: 10.1073/pnas.1405889111.

16.

Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.

Meyer D, Sielaff F, Hammami M, Böttcher-Friebertshäuser E, Garten W, Steinmetzer T.

Biochem J. 2013 Jun 1;452(2):331-43. doi: 10.1042/BJ20130101.

PMID:
23527573
17.

Protease-mediated entry via the endosome of human coronavirus 229E.

Kawase M, Shirato K, Matsuyama S, Taguchi F.

J Virol. 2009 Jan;83(2):712-21. doi: 10.1128/JVI.01933-08.

18.

Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection.

Barlan A, Zhao J, Sarkar MK, Li K, McCray PB Jr, Perlman S, Gallagher T.

J Virol. 2014 May;88(9):4953-61. doi: 10.1128/JVI.00161-14.

19.

Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity.

Gierer S, Müller MA, Heurich A, Ritz D, Springstein BL, Karsten CB, Schendzielorz A, Gnirß K, Drosten C, Pöhlmann S.

J Infect Dis. 2015 Mar 15;211(6):889-97. doi: 10.1093/infdis/jiu407.

20.

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein.

Millet JK, Whittaker GR.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9. doi: 10.1073/pnas.1407087111.

Items per page

Supplemental Content

Support Center